20 results about "Streptozotocin" patented technology

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I).Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and / or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

The invention discloses a medicine for treating diabetic retinopathy and application of scorpion venom heat-resistant synthetic peptide in treating the disease, belongs to the field of research and development of polypeptide medicines, and is used for treating or preventing the diabetic retinopathy (DR). Experimental results show that the scorpion venom heat-resistant synthetic peptide (SVHRSP) has the effect of preventing and treating diabetic retinopathy (DR) on a streptozotocin (STZ)-induced mouse experimental diabetes model, and can repress retinal function impairment caused by impairment of streptozotocin (STZ)-induced diabetic mouse retinal photoreceptor cells and retinal nerve inner layer cells; and retina structure damage caused by thinning of the retina thickness of a diabetic mouse induced by STZ (streptozotocin) is inhibited.

The invention discloses a preparation method of high-purity sugarcane leaf polysaccharide, which comprises the following steps: separating sugarcane leaf crude polysaccharide by using an alkaline H2O2 method, and then separating and purifying by using a DEAE-Sepharose Fast Flow anion exchange column to obtain the high-purity sugarcane leaf polysaccharide SLP-2. The monosaccharide composition of the high-purity sugarcane leaf polysaccharide SLP-2 is mainly Xyl, Ara and Gal, and the main chain structure of the high-purity sugarcane leaf polysaccharide SLP-2 is composed of glycosidic bonds such as Araf-(1-), Xylp-(1-),-> 3, 4)-Galp-(1-),-> 5)-Araf-(1-),-> 4)-Xylp-(1-),-> 4)-Glcp-(1-),-> 3, 4)-Xylp-(1-) and the like. The research on the efficacy of a diabetic cardiomyopathy rat model induced by feeding with streptozotocin combined with high-sugar and high-fat feed finds that the high-purity sugarcane leaf polysaccharide SLP-2 has the effects of reducing the blood sugar of the diabetic cardiomyopathy rat and improving the heart function of the diabetic cardiomyopathy rat. In conclusion, the preparation process is simple, the polysaccharide composition and structure are clear, and the SLP-2 has good effects of reducing blood sugar and improving diabetic cardiomyopathy and heart injury, has a certain application prospect in the field of medicines, and is worthy of further research.

The invention discloses application of an HSPA13 gene in preparation of a product for improving diabetic cardiomyopathy, and belongs to the technical field of gene engineering. Aiming at the technical problems of myocardial microvascular endothelial cell glycolysis damage, perfusion insufficiency and cardiac dysfunction caused by long-term hyperglycemia, the invention firstly proves that in a streptozotocin-induced type 1 diabetes mouse model, the expression of HSPA13 in myocardial microvascular endothelial cells is remarkably reduced, and then an endothelium-targeted adeno-associated virus vector AAV-HSPA13 is constructed; and intravenous administration is carried out. Experimental results show that the vector can recover the endothelial glycolysis level, improve coronary flow reserve and significantly relieve the pathological change of DCM. The HSPA13 gene is taken as a core target, can be used for preparing or screening a pharmaceutical composition or a function evaluation model for treating DCM, and has outstanding innovativeness and clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

The application belongs to the technical field of medical evaluation and detection, and particularly relates to a method for constructing an animal model of diabetes combined with kidney lipid injury. The method comprises the following steps: taking experimental animals, feeding the animals with high-fat feed for 3-5 weeks, feeding the animals with ordinary feed for 4-6 days in succession, injecting streptozotocin into the abdominal cavity of the animals, the amount of streptozotocin injected into each animal per day being 35-45 mg / Kg, and then feeding the animals with high-fat feed for 11-13 weeks, so that a disease animal of diabetes combined with kidney lipid injury is obtained. The disease animal model of diabetes combined with kidney lipid injury has high repeatability, prominent kidney lipid injury, and simple operation, and has important value and significance in basic research.

This invention belongs to the field of biomaterials technology, specifically relating to a bioactive scaffold, its preparation method, and its applications. This invention incorporates functionalized mesoporous silica nanoparticles loaded with aminoguanidine into the skin secretions of the giant salamander and polycaprolactone electrospun fibers to construct a bioactive composite scaffold (SPMA). This scaffold enables the sustained release of AG and osteogenic factors, effectively inhibiting free radical generation, AGEs toxicity, and inflammatory responses. Furthermore, it significantly improves the survival rate, osteogenic differentiation, and mineralization capacity of bone marrow mesenchymal stem cells in a high-glucose microenvironment. In vivo experiments further demonstrate that in a streptozotocin-induced diabetic mouse model of skull defects, the SPMA scaffold can alleviate local inflammation, promote angiogenesis, and significantly accelerate new bone formation and defect repair.

The invention provides a biological product for regulating blood sugar of type I diabetes mellitus, and belongs to the technical field of diabetes mellitus treatment. The biological product is a composite biological product composed of aronia melanocarpa polysaccharide (AMP) and rhizoma bletillae polysaccharide (BSP). In-vitro cell and in-vivo animal experiments find that the compound polysaccharide can significantly improve the survival rate of islet beta cells damaged by streptozotocin (STZ) and promote insulin secretion. Experimental results show that when the two polysaccharides are combined for use, especially when the two polysaccharides are combined in a ratio of 9: 1, the effects of reducing blood sugar and improving insulin secretion level are obviously better than those of a monomer, and a Bliss model verifies that the two polysaccharides have a synergistic effect. Therefore, the invention provides an efficient and natural new treatment strategy for the treatment of the type I diabetes mellitus.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of a drug for treating sarcopenia, wherein the traditional Chinese medicine composition consists of Astragalus membranaceus and Anemarrhena asphodeloides. The study found that the combination of Astragalus membranaceus and Anemarrhena asphodeloides can significantly improve the differentiation function of C2C12 myoblasts induced by high glucose and inhibit lipid deposition, and improve skeletal muscle mass, muscle strength, and motor function in a streptozotocin-induced C57BL / 6 diabetic sarcopenia mouse model. In vitro and in vivo experiments have confirmed that this drug has significant effects in improving muscle atrophy, enhancing motor function, and restoring muscle strength; it can effectively increase the cross-sectional area of ​​muscle fibers, promote myotube fusion, and accelerate damage repair, showing a clear potential to inhibit diabetic muscle atrophy. This provides an effective traditional Chinese medicine compound intervention strategy for the clinical treatment of diabetic sarcopenia and has good prospects for development and application.

The present invention discloses the application of streptozotocin for antibacterial and combined antibacterial activity. The present invention discloses that streptozotocin has broad-spectrum antibacterial activity against both drug-resistant Gram-positive and Gram-negative bacteria. Furthermore, when used in combination with other antibacterial drugs, streptozotocin exhibits additive or synergistic antibacterial activity against drug-resistant bacteria. This can address the current shortage of clinical anti-resistant bacteria drugs, improve efficacy, and reduce the spread of drug-resistant bacteria.

The invention discloses parabacteroides capable of improving type II diabetes mellitus, and belongs to the technical field of microorganisms. According to the invention, a T2DM mouse model induced by high fat diet and high fat combined with intraperitoneal injection streptozotocin (STZ) is established, a key strain Pd-A2 is screened from fucoidin-intervened same-model mouse metabolic species, and the relieving effect of the key strain Pd-A2 on T2DM mice is analyzed. The method specifically comprises the following steps: (1) reducing the content of MDA and MPO in the liver of a mouse, and improving the level of SOD and CAT; (2) reducing the fasting blood-glucose of the mouse; (3) the sugar tolerance of the mouse is improved; (4) reducing the content of AST and ALT in serum of the mouse; and (5) reducing the content of cholesterol and triglyceride in serum of the mouse. Therefore, the key strain Pd-A2 screened by the invention has the improvement effect on the type II diabetes mellitus.

The invention discloses an equivalent component group of Gegen Qinlian decoction for improving type 2 diabetes mellitus and application of the equivalent component group. The invention provides an equivalent component group for treating type 2 diabetes mellitus by using a Gegen Qinlian decoction. The equivalent component group consists of 13, 19 or 27 chemical components. A zebra fish diabetes model and a high fat diet combined streptozotocin induced type 2 diabetes mouse model prove that the equivalent component group consisting of 13, 19 or 27 chemical components has an obvious treatment effect on type 2 diabetes, the treatment effect is not remarkably different from that of the original formula of the Gegen Qinlian decoction, and the excellent equivalence is shown. Therefore, the composition provided by the invention can be used as an equivalent component group of the Gegen Qinlian decoction for treating the type 2 diabetes mellitus, and is further used for preparing a medicine for equivalently replacing the Gegen Qinlian decoction for improving the type 2 diabetes mellitus, or is used for preparing a composition for controlling the quality of the Gegen Qinlian decoction.

The invention discloses application of < 18 > F-lactitol in preparation of a diabetic nephropathy detection product, and belongs to the technical field of biomedical detection. In order to solve the problem that the action and mechanism of STRs in the kidney through SGLT2-dependent glucose reabsorption and transport are not clear yet, 18F-labeled lactitol is used, the in-vivo glucose level, kidney pathology and SGLT2 expression are detected through PET / CT, and the glucose uptake rate is labeled through in-vitro fluorescence, so that the effect and mechanism of STRs in the kidney through SGLT2-dependent glucose reabsorption and transport are determined. The method is used for evaluating the glucose reabsorption effect and mechanism of the STRs in STZ (streptozotocin)-induced diabetic mice and HK-2 cells. The result shows that the 18F-lactitol can be sensitively and specifically combined with the STRs, the biological distribution of the 18F-lactitol and the expression of the STRs in the kidney of a diabetic mouse are obviously reduced, the expression of the SGLT2 is up-regulated, and the lactitol or siRNA-STRs can obviously reduce the influence of high glucose on the expression of the STRs and the SGLT2 and glucose absorption. Therefore, the STRs can be used as a new therapeutic target for diabetes, and the < 18 > F-lactitol labeled PET / CT can become a novel probe for detecting diabetic kidney injury.

The invention relates to the technical field of biomedical experimental animal models, in particular to a drug induction-based miniature pig diabetes mellitus model construction method and application. The drug-induced miniature pig diabetes model construction method comprises the following steps: mixing a citric acid solution with a sodium citrate solution to obtain a mixed solution, and adjusting the pH value of the mixed solution to 4.2-5.0 to obtain a citric acid buffer solution; under the dark condition, streptozotocin is dissolved in the citric acid buffer solution, and a streptozotocin solution is obtained; the prepared streptozotocin solution is injected into the ear edge vein of the fasting miniature pig at a time, and construction of the miniature pig diabetes mellitus model is completed; the injection dosage in the step S3 is 140 to 160 mg / kg. The construction steps of the miniature pig diabetes model are simplified, the long-term stable miniature pig diabetes model can be constructed, and a simpler, more convenient and more stable model construction method is provided for research on a miniature pig diabetes disease mechanism and a treatment method.

The invention belongs to the technical field of animal biology, and particularly relates to a pancreatic cancer related diabetes mouse model construction method, which comprises: preparing a pancreatic cancer cell suspension; preparing a streptozotocin solution; injecting the pancreatic cancer cell suspension to the pancreatic head of the pancreas of the mouse, and establishing a pancreatic cancer model; and 3-5 days after injection is completed, continuously carrying out intraperitoneal injection on the mouse by utilizing a streptozotocin solution once a day, and continuously carrying out injection for 3-5 days, so as to obtain the pancreatic cancer related diabetes mouse model. The animal model of pancreatic cancer related diabetes mellitus is successfully constructed through pancreatic cancer orthotopic transplantation tumor and intraperitoneal injection of STZ, and the model shows wide application potential in the fields of basic and clinical research.

The invention provides application of a compound shown in a formula (I) in preparation of a medicine for improving male reproductive capacity. According to the application, a nano micro-plastic and plasticizer induced Kunming mouse environment pollution type oligospermia and asthenospermia model, a streptozotocin induced Kunming mouse diabetes type oligospermia and asthenospermia model and a sodium valproate induced Kunming mouse anti-epileptic drug type oligospermia and asthenospermia model are respectively constructed; the improvement effect of the compound shown in the formula (I) on male reproductive capacity damage is verified through sperm counting analysis, sperm motility analysis, inflammation and antioxidant gene mRNA expression level analysis, testis tissue pathological damage analysis and the like, and experimental results show that the compound shown in the formula (I) increases the sperm number of mice suffering from oligospermia and asthenospermia, and has a good application prospect. According to the application, the sperm motility of mice with oligospermia and asthenozoospermia is improved, the tissue pathological damage of the testis is improved, the expression of inflammatory factors is inhibited, the expression of antioxidant genes is increased, and the application has great potential in the aspect of treating oligospermia and asthenozoospermia.

The present invention provides a biological product for regulating blood sugar in type 1 diabetes, belonging to the technical field of diabetes treatment. The biological product is a composite biological product composed of Aralia melanocarpa polysaccharide (AMP) and Bletilla striata polysaccharide (BSP). In vitro cell and in vivo animal experiments have shown that the composite polysaccharide can significantly improve the survival rate of pancreatic β cells damaged by streptozotocin (STZ) and promote insulin secretion. Experimental results show that the combination of the two polysaccharides, especially when combined in a 9:1 ratio, is significantly more effective in lowering blood sugar and increasing insulin secretion levels than the use of the two polysaccharides alone, and the Bliss model has been verified to have a synergistic effect. Therefore, the present invention provides a new, efficient and natural treatment strategy for the treatment of type 1 diabetes.

The invention discloses an application of malic acid in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that malic acid can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; malic acid can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; the malic acid is used for activating a PI3K / AKT signal channel to up-regulate the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulate the expression of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the malic acid has a protection or repair effect on liver injury.